Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Phase II Iressa & Carbo/Gem in NSCLC

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Gemcitabine
Drug: Gefitinib
Drug: Carboplatin

First Posted Date: 2005-12-13

Last Posted Date: 2009-08-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 38

Registration Number: NCT00264498

Locations: 🇨🇦
Research Site, Montreal, Quebec, Canada

Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer
Extensive Stage Unresectable

First Posted Date: 2005-12-12

Last Posted Date: 2010-01-20

Lead Sponsor: Kentuckiana Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00264134

Locations: 🇺🇸
Kentuckiana Cancer Institute, Louisville, Kentucky, United States

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3

Completed

Conditions: Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Serous Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Malignant Ovarian Mixed Epithelial Tumor
Ovarian Brenner Tumor
Ovarian Clear Cell Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Adenocarcinoma

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Carboplatin
Other: Placebo
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2005-12-07

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1873

Registration Number: NCT00262847

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Memorial Hospital at Easton - Shore Regional Cancer Center, Easton, Maryland, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 622 locations

Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: carboplatin
Drug: docetaxel
Radiation: radiation therapy

First Posted Date: 2005-11-24

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 41

Registration Number: NCT00258362

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: carboplatin
Drug: etoposide
Drug: ifosfamide

First Posted Date: 2005-11-21

Last Posted Date: 2016-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 98

Registration Number: NCT00255723

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Carboplatin
Drug: GM-CSF
Drug: Trastuzumab

First Posted Date: 2005-11-21

Last Posted Date: 2018-03-02

Lead Sponsor: Rita Sanghvi, Mehta

Target Recruit Count: 48

Registration Number: NCT00256243

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Stage IV Melanoma
Recurrent Melanoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2005-11-21

Last Posted Date: 2013-10-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00255762

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Neoadjuvant Treatment of Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Nab-paclitaxel
Drug: GM-CSF
Drug: Trastuzumab
Drug: Bevacizumab

First Posted Date: 2005-11-16

Last Posted Date: 2019-02-28

Lead Sponsor: University of California, Irvine

Target Recruit Count: 43

Registration Number: NCT00254592

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Carcinoma

First Posted Date: 2005-11-15

Last Posted Date: 2007-12-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 44

Registration Number: NCT00252798

Locations: 🇦🇺
Research Site, East Melbourne, Victoria, Australia

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Biological: Filgrastim
Drug: Carboplatin
Drug: Etoposide
Drug: Melphalan
Procedure: Peripheral blood stem cell infusion
Radiation: 131I-MIBG
Radiation: Radiation therapy

First Posted Date: 2005-11-15

Last Posted Date: 2023-04-10

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 50

Registration Number: NCT00253435

Locations: 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of Chicago Comer Children's Hospital, Chicago, Illinois, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy